ABOS
Acumen Pharmaceuticals, Inc. Healthcare Biotechnology
5/12
Innovation Score
Patent Activity
0/3
No patents found in USPTO database (last 2026-05-11 02:16).
Cash Runway
1/3
12 months of cash remaining based on current burn rate.
Cash on hand: $116.9M
Cash on hand: $116.9M
Revenue Trajectory
1/3
Revenue: $0.0M
Revenue growth data unavailable.
Revenue growth data unavailable.
Management Quality
3/3
Insider ownership: 48.8%
SBC/Revenue: 0.0%
No reverse splits detected
SBC/Revenue: 0.0%
No reverse splits detected
Key Metrics
Market Cap
$184.9M
Revenue
$0.0M
Revenue Growth (YoY)
N/A
Cash on Hand
$116.9M
Cash Runway
12 months
Shares Outstanding
72.2M
Insider Ownership
48.8%
SBC / Revenue
0.0%
Sector / Industry
Healthcare / Biotechnology
7-Step Risk Assessment
How ABOS maps to our micro cap methodology:
- Innovation Signal No patents found. Innovation may be trade-secret-based or too early for filings.
- Cash Runway Check 12 months of runway. Short runway increases dilution risk — watch for capital raises.
- Revenue Trajectory Revenue data unavailable.
- Management Alignment Insiders hold 48.8% of shares. SBC is 0.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $184.9M company.
Financial Detail
Free Cash Flow
$-75.1M
FCF Yield
-40.6%
Return on Equity
-96.2%
Debt / Equity
44.5%
Gross Margin
N/A
Profit Margin
N/A
Operating Margin
N/A
Price / Book
2.20
Current Ratio
4.07
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Quality Flags
Low Debt
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-05-11